Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease

NCT ID: NCT02332356

Last Updated: 2023-11-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2024-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized, controlled study aims to evaluate the impact of therapeutic intervention (step up) for the patients who are clinical remission with Magnetic Resonance Enterocolonography (MREC) active. In addition, to evaluate the impact of therapeutic step down for the patients who archived clinical and MREC remission. The primary endpoint is the rate of clinical remission at 104 weeks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

step up

Procedure: MREC patients receive therapeutic step up

Group Type ACTIVE_COMPARATOR

azathioprine or adalimumab and infliximab

Intervention Type DRUG

observation step up

Group Type NO_INTERVENTION

No interventions assigned to this group

step down

Procedure: MREC patients receive therapeutic step down

Group Type ACTIVE_COMPARATOR

azathioprine or adalimumab and infliximab

Intervention Type DRUG

observation step down

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

azathioprine or adalimumab and infliximab

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of Crohn's and proven history of disease with clinical remission (CDAI\<150)
* Signed written consent form to enroll the study (Need agreement from deputy for patients under 20years old)

Exclusion Criteria

* Contraindication for infliximab, adalimumab, or azathioprine
* Lactating woman
* Presence of malignancy
* Within 3 month from intestinal surgery
* Presence of an end stoma
* Planned surgery
Minimum Eligible Age

16 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tokyo Medical and Dental University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Toshimitsu Fujii, MD PhD

Gastroenterology and Hepatology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Toshimitsu Fujii

Role: PRINCIPAL_INVESTIGATOR

Tokyo Medical and Dental University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gastroenterology and Hepatology, Tokyo Medical and Dental UNIV

Tokyo, , Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

References

Explore related publications, articles, or registry entries linked to this study.

Takenaka K, Ohtsuka K, Kitazume Y, Nagahori M, Fujii T, Saito E, Naganuma M, Araki A, Watanabe M. Comparison of magnetic resonance and balloon enteroscopic examination of the small intestine in patients with Crohn's disease. Gastroenterology. 2014 Aug;147(2):334-342.e3. doi: 10.1053/j.gastro.2014.04.008. Epub 2014 Apr 13.

Reference Type BACKGROUND
PMID: 24732015 (View on PubMed)

Hyun SB, Kitazume Y, Nagahori M, Toriihara A, Fujii T, Tsuchiya K, Suzuki S, Okada E, Araki A, Naganuma M, Watanabe M. Magnetic resonance enterocolonography is useful for simultaneous evaluation of small and large intestinal lesions in Crohn's disease. Inflamm Bowel Dis. 2011 May;17(5):1063-72. doi: 10.1002/ibd.21510. Epub 2010 Oct 25.

Reference Type BACKGROUND
PMID: 21484957 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MREC study

Identifier Type: -

Identifier Source: org_study_id